News March 12, 2019: Centurion BioPharma Corporation’s Albumin Companion Diagnostic (ACDx) Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery SystemsFebruary 13, 2019: Centurion BioPharma Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the TumorFebruary 11, 2019: Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for ChemotherapyJune 4, 2018: Centurion BioPharma Corporation Launches to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates
